Diagnostics News and Research

RSS

Western, Midwestern states register higher methamphetamine usage

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today issued its annual report on U.S. worker drug use, the Quest Diagnostics Drug Testing Index.

From Quest Diagnostics 2 Sep 2011

AmerisourceBergen completes acquisition of Premier Source

AmerisourceBergen Corporation today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies.

2 Sep 2011

Special journal edition chronicles 3-D structures of important antibacterial, bioterrorist targets

The September issue of the online scientific journal Acta Crystallographica: Structural Biology and Crystallization Communications (Acta Cryst F) will consist entirely of work done at the Seattle Structural Genomics Center for Infectious Disease (SSGCID), a consortium of researchers from Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory.

2 Sep 2011

Low-cost, portable technique can detect specific proteins in human blood

Blood tests are important diagnostic tools. They accurately tease-out vanishingly small concentrations of proteins and other molecules that help give a picture of overall health or signal the presence of specific diseases. Current testing procedures, however, are expensive and time-consuming, while sophisticated test equipment is bulky and difficult to transport.

2 Sep 2011

Microvisk introduces unique handheld device which monitors blood clotting status

Microvisk Technologies has introduced its unique handheld devices which monitor the blood clotting status of patients to the US market. Showcased at the prestigious American Association for Clinical Chemistry annual conference, the Microvisk devices attracted strong interest from distributors and potential partners ahead of clinical trials in major US medical centres this autumn and product launches in 2012.

31 Aug 2011

Medical professionals play a role in prevention of abuse, harassment and bullying in sport

Sport and exercise medicine professionals have an important responsibility to protect the athletes under their care against abuse, harassment, and bullying, according to a position paper published in the September issue of Clinical Journal of Sport Medicine.

31 Aug 2011

UCLA develops dual-mode microscope that uses holograms instead of lenses

To serve remote areas of the world, doctors, nurses and field workers need equipment that is portable, versatile, and relatively inexpensive. Now researchers at the University of California at Los Angeles (UCLA) have built a compact, light-weight, dual-mode microscope that uses holograms instead of lenses.

31 Aug 2011

Alcon chooses Bruker ContourGT-X8 Optical Surface Profiler

Bruker announced today that Alcon Corporation has selected the Bruker ContourGT-X8 Optical Surface Profiler to provide non-destructive, non-contact reference metrology for critical dimensioning and 3D characterization of Alcon's current and next-generation intra-ocular lenses.

From Bruker Nano Surfaces and Metrology 30 Aug 2011

HTG announces availability of qDiscovery miRNA WTA Version 16

HTG Molecular Diagnostics today announced the availability of the qDiscovery miRNA Whole Transcriptome Array (WTA) Version 16, a complete solution for microRNA (miRNA) analysis on any sample type or size.

30 Aug 2011

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR), has signed an exclusive license with Amorfix Life Sciences Ltd. of Missisauga, Ontario for the use of their proprietary ProMIS technology in developing vaccines (active immunotherapy) for the treatment of diseases caused by the formation of misfolded prion.

29 Aug 2011

SQI Diagnostics third quarter net loss increases to $2,691,000

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the third quarter ended June 30, 2011.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

QIAGEN acquires Cellestis

QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.

From QIAGEN Manchester Limited 29 Aug 2011

Low-cost device to help physicians detect and diagnose cancer

An engineering researcher and a global health expert from Michigan State University are working on bringing a low-cost, hand-held device to nations with limited resources to help physicians detect and diagnose cancer.

29 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

New test to better predict heart attack risk in women

The biggest killer of women over the age of 50 is heart disease. By age 65 women have the same heart attack or stroke risk as men and a greater risk of dying from either. To help better predict heart attack risk in these women, Atherotech Diagnostics Lab has developed a new and better way to test for heart disease risk. The new test will soon be available exclusively through Atherotech Diagnostics Lab.

26 Aug 2011